FDA’s Proposed Guidance for Laboratory Developed Tests: How Should Regulators Balance the Risks and Promise of Innovation in Clinical Genetics?

Documenti analoghi

• The FDA’s New Guidance for Off-Label Promotion Is Only a Start
  di: Field, Robert I.
  Pubblicazione: (2008)
• FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine
  di: Luh, Frank, et al.
  Pubblicazione: (2018)
• FDA’s commitment to transparency
  di: Guharoy, Roy, et al.
  Pubblicazione: (2021)
• Pharmacists Welcome FDA’s Opioids REMS: How Directly Will They Be Affected?
  di: Barlas, Stephen
  Pubblicazione: (2012)
• Rethinking FDA’s2013 Guidance on Developing Drugs for Early Stage Alzheimer Disease
  di: Schneider, Lon S.
  Pubblicazione: (2014)